Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: Cancer Lett. 2023 Jun 24;568:216284. doi: 10.1016/j.canlet.2023.216284

Table 2.

Combinations Reducing MYC (n = 10) and Increasing p16 (n = 6) Protein Expression in L363 MM Cells

Reduced MYC Protein Expression vs. Single Agent/Control in L363 MM Cells
Drug 1 Primary Target 1 Drug 2 Primary Target 2 r2 (Robust
Regr.)
†p16 vs. Ctrl
BS-194 CDK1 Dacinostat HDAC1 0.634
Alisertib AURKA Doxorubicin TOP2A 0.655
Geldanamycin HSP90 Idarubicin HCl TOP2A 0.540
Noscapine TUBB IVX-214 PLK1 0.583
XRP-44X TUBB IVX-214 PLK1 0.606
BS-194 CDK1 VER-82576 HSP90 0.571
AT13387AU HSP90 ITK(3) ITK 0.634 x
SNX-5422 HSP90 ITK(3) ITK 0.702 x
VER-82576 HSP90 ITK(1) ITK 0.836 x
VU-482089 MCL1 AV-412 EGFR 0.535 x